The Galway medtech company Aerogen will be creating 725 new jobs over the next ten years from a €300 million investment plan.
Aerogen technology has been used to treat over 25 million patients in emergency departments, adult and paediatric ICUs, general wards and ambulance services in 75 countries worldwide.
Aerogen offers a safe and powerful drug delivery device for the treatment of critical respiratory illness and other non-respiratory illnesses and is the leading manufacturer of high performance, single-use, respiratory nebulisers in the world.
The Aerogen Group is headquartered in Dangan, Galway and the new Irish jobs will be across R&D, manufacturing, science and engineering and located there and at its two manufacturing sites in Parkmore, Galway and Shannon.
The implementation of the transformational scaling plan will enable Aerogen to create up to 725 highly skilled jobs in the West by 2035 increasing its global workforce to over 2,000 of which over 1,100 will be based in Ireland.
Now 25 years in operation, Aerogen has revenues of over €150 million and has contributed €130 million to local Irish businesses.
Over the next five years Aerogen expects to contribute a further €250 million in income and corporation taxes, directly benefiting the Irish economy.
John Power, CEO and Founder of Aerogen said, “We are delighted to announce this continued expansion of Aerogen as a truly global life science company.”
“Enterprise Ireland have been a superb partner in supporting this journey on which we just reached the pivotal milestone of having treated our 25th millionth patient, and we will continue to innovate across the respiratory journey for patients from our HQ here in Galway.”
Aerogen holds more than 300 international patents and published more than 200 clinical papers in its medtech research and development.
The new 10 year scaling strategy will see the company expand its existing device technology, and also build its emerging biopharmaceutics business.
This will be achieved with a major breakthrough in treating premature newborns with Infant Respiratory Stress Syndrome.
Minister for Enterprise, Trade and Employment Peter Burke was on site in Galway to preside over Aerogen’s growth announcement.
“The government through Enterprise Ireland is targeting ambitious scaling of Irish multinationals that will help drive the Irish economy and our competitive advantage forward.”
“Aerogen’s announcement today is evidence of that Irish multinational ambition in action, and we are delighted to support them on their patient-focused mission.
The expansion is supported by Enterprise Ireland, who welcome the creation of high value jobs and the strengthening of Ireland’s position in the global value chain of medical technology and manufacturing.
Leo Clancy, CEO, Enterprise Ireland said, “Ambitious companies like Aerogen embody Enterprise Ireland’s vision – that Irish owned, globally focused companies will be the primary driver of our economy.”
“Aerogen has the potential and ambition to achieve billions in revenue, joining the ranks of industry-leading Irish multinationals.”
